Newer therapies, such as Glucagon-like peptide-1 (GLP-1) receptor agonists (also known as incretin mimetics) have been studied as an adjunct to insulin in T1D, with mixed results26,27. The gene discussed is GLP1R; the disease is type 1 diabetes mellitus.